Supernus Pharmaceuticals is showcasing Qelbree at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
Qelbree is Supernus's commercial anchor — a non-stimulant ADHD treatment in a market where stimulant concerns are growing. At APA, they'll emphasize the non-stimulant mechanism, no DEA scheduling, and suitability for patients who can't or won't take stimulants. The psilocybin pipeline (SYNP-101) may get a mention but won't be the booth focus.
Ask about: Qelbree real-world prescribing trends vs. atomoxetine (the other non-stimulant); adult ADHD uptake; formulary positioning; how they see Qelbree coexisting with solriamfetol (Axsome's Phase 3 non-stimulant ADHD competitor); psilocybin (SYNP-101) strategy as a longer-term conversation piece.
ePRO+ captures real-world ADHD functional outcomes beyond symptom scores. VoiceVitals measures attention and cognitive performance. For Qelbree, the evidence story is non-stimulant efficacy in real-world settings — Videra can generate that data at scale.
Set up a follow-up with Supernus Pharmaceuticals's team and Videra Health.
Email Ryan Roberts →